NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-02 14:48இன்று 78 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
PGHL Q2 FY27 Results: Sales Up 18% to ₹376 Cr, PAT Rises 26% to ₹112 Cr
Procter & Gamble Health announced strong financial results for its second quarter ended September 30, 2026. Sales grew 18% year-over-year to ₹376 crore, supported by retail execution, go-to-market improvements, and consumer uptake of innovations. Net profit (PAT) increased by 26% year-over-year to ₹112 crore, driven by top-line gains and operating productivity across the supply chain.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its unaudited financial performance for Q2 ended September 30, 2026, delivering 18% sales growth and 26% PAT growth.
ஏன் இது முக்கியம்Demonstrates robust operating leverage and pricing resilience in PGHL's core vitamins, minerals, and supplements (VMS) portfolio despite ongoing regulatory pricing caps.
📅 குறுகிய காலம்Market sentiment is likely to respond positively to strong double-digit growth in both sales and earnings for the quarter.
📈 நீண்ட காலம்Structural growth remains anchored to expanding rural coverage, doctor advocacy, and consumer shift toward preventive health, balanced against DPCO price ceiling risks.
⚠ அபாய எச்சரிக்கைகள்
DPCO price controls limiting pass-through of raw material cost inflation
High product concentration in the vitamin and supplement segment
👀 கவனிக்க வேண்டியவை
Track whether double-digit top-line momentum and margins can be sustained in subsequent quarters amid DPCO price constraints on core formulations.
45% PAT growth to ₹96 cr in Q1 FY27; Operational PAT up 9% on ₹356 cr sales
Procter & Gamble Health Limited (PGHL) reported a 7% YoY increase in sales to ₹356 crores for the quarter ended June 30, 2026. Reported Profit After Tax (PAT) surged 45% to ₹96 crores, significantly aided by one-time proceeds from the sale of an immovable asset. Excluding this one-time gain, operational PAT grew by 9% to ₹72 crores. The company continues to leverage its strong brands like Neurobion and Evion, maintaining a high ROCE of 84% and a very low debt-to-equity ratio of 0.02.
உச்சம் நம்பிக்கை
என்ன மாறியதுPGHL reported its first-quarter results for FY 2026-27, showing steady operational growth and a significant one-time profit boost from an asset sale.
ஏன் இது முக்கியம்The results confirm the resilience of the company's Vitamin, Mineral, and Supplement (VMS) portfolio and its ability to generate high returns (84% ROCE) while maintaining a nearly debt-free balance sheet.
Sales (Q1 FY27): ₹356 கோடிReported PAT (Q1 FY27): ₹96 கோடிOperational PAT (Q1 FY27): ₹72 கோடிSales Growth (YoY): 7%Operational PAT Growth (YoY): 9%ROCE: 84.0%
📅 குறுகிய காலம்The stock may see positive momentum due to the headline 45% PAT growth, although the market will likely adjust for the one-time asset sale gain.
📈 நீண்ட காலம்The company remains a strong player in the Indian VMS market with high capital efficiency; long-term growth depends on rural expansion and new product innovations.
⚠ அபாய எச்சரிக்கைகள்
High product concentration in the Vitamin segment
Pricing constraints due to Drug Price Control Order (DPCO) regulations
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the 9% operational PAT growth and track how the company manages pricing under DPCO regulations to maintain margins in the VMS segment.
PGHL Q1 Results: Net Profit Rises 45% to ₹96.15 Cr, Aided by ₹31.8 Cr Property Sale
Procter & Gamble Health Limited (PGHL) reported a steady 7.4% YoY revenue growth to ₹363.71 Cr for the quarter ended June 30, 2026. Net profit surged 45.3% YoY to ₹96.15 Cr, though this was significantly bolstered by a one-time exceptional gain of ₹31.80 Cr from the sale of its Worli office premises. Excluding this gain, Profit Before Tax (PBT) stood at ₹97.31 Cr, a 9.6% increase over the ₹88.81 Cr reported in the same quarter last year. The company continues to operate with a very strong ROCE of 84% and minimal debt of ₹9 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுPGHL reported its quarterly financial results and completed the divestment of its Worli office premises, resulting in a significant one-time profit boost.
ஏன் இது முக்கியம்The results demonstrate steady growth in the core pharmaceutical/VMS business, while the property sale strengthens the cash position of an already debt-free, high-ROCE company.
Revenue (Q1 FY27): ₹363.71 கோடிNet Profit (Q1 FY27): ₹96.15 கோடிExceptional Gain: ₹31.80 கோடிGain vs Net Worth: 6.06%YoY Revenue Growth: 7.37%
📅 குறுகிய காலம்The stock may see positive momentum due to the headline profit growth, though the market will likely adjust for the non-recurring nature of the property sale gain.
📈 நீண்ட காலம்The long-term outlook remains tied to the company's ability to expand its VMS portfolio and rural reach under its 'Integrated Growth Strategy' despite regulatory pricing pressures.
⚠ அபாய எச்சரிக்கைகள்
High product concentration in the Vitamin segment
Pricing constraints due to Drug Price Control Order (DPCO)
One-time nature of the current profit surge
👀 கவனிக்க வேண்டியவை
Investors should focus on the core operational performance excluding the one-time property gain to assess sustainable growth. Watch for the impact of DPCO pricing regulations on margins in the upcoming quarters.
PGHL Announces ₹45 Final Dividend for FY 2025-26 and Issues TDS Guidelines
Procter & Gamble Health Limited (PGHL) has recommended a final dividend of ₹45 per equity share for the financial year 2025-26, subject to shareholder approval. The company has released detailed instructions regarding Tax Deducted at Source (TDS) on this dividend, which is taxable in the hands of shareholders. Resident shareholders with a valid PAN will be subject to a 10% TDS, while those without a valid PAN or linked Aadhaar will face a 20% deduction. Shareholders must submit relevant tax exemption documents or residency certificates by August 12, 2026, to ensure the correct tax rate is applied.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹45 per equity share of face value ₹10 for FY 2025-26.Standard TDS rate of 10% for resident shareholders with a valid PAN and linked Aadhaar.Higher TDS rate of 20% for resident shareholders with invalid PAN or missing Aadhaar-PAN linkage.No TDS for individual resident shareholders if the total dividend for the year does not exceed ₹10,000.Deadline for submitting tax-related declarations and documents is August 12, 2026.
👀 கவனிக்க வேண்டியவை
Shareholders should verify that their PAN is correctly updated and linked with Aadhaar in their demat accounts to avoid a higher 20% tax deduction. Eligible investors seeking tax exemptions should submit Form 121 or other required documents on the KFintech portal before the August 12 deadline.
PGHL Reports 30% PAT Growth to ₹327 Crore in FY26; Sales Up 16% to ₹1,400 Crore
Procter & Gamble Health Limited (PGHL) delivered a robust financial performance for the fiscal year ended March 31, 2026, with sales reaching approximately ₹1,400 crore, a 16% year-on-year increase. Profit After Tax (PAT) surged by 30% to ₹327 crore, supported by a 16% growth in the top line and significant productivity gains. The company is focusing on 'irresistible superiority' through new launches like Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream to address high-prevalence health gaps in India. Management also reported ₹35 crore in productivity savings, which are being reinvested into brand building and margin expansion.
முக்கிய அம்சங்கள்
Annual sales grew 16% YoY to reach approximately ₹1,400 crore for the fiscal year ended March 2026.Profit After Tax (PAT) increased by 30% YoY to ₹327 crore, significantly outpacing revenue growth.Achieved ₹35 crore in savings through targeted productivity and efficiency programs across the value chain.Introduced high-potential innovations including Livogen Iron Gummies, Neurobion Nerve Pain Relief Cream, and Evion L5000.Maintained strong market position in Vitamin B, Iron, and Vitamin E categories with brands like Neurobion, Livogen, and Evion.
👀 கவனிக்க வேண்டியவை
Investors should take note of the strong margin expansion and the company's ability to grow its bottom line at nearly double the rate of its top line. The successful rollout of new formats like gummies and topical creams indicates a strong innovation pipeline that could drive future market share gains.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
PGHL Q4 PAT Surges 55% to ₹95 Cr; Total FY26 Dividend Declared at ₹205 Per Share
Procter & Gamble Health Limited (PGHL) reported a strong Q4 FY26 with sales growing 20% YoY to ₹365 crores and PAT jumping 55% to ₹95 crores. For the full fiscal year, the company achieved sales of ₹1385 crores and a PAT of ₹327 crores, representing a 16% and 30% growth respectively on a comparable 12-month basis. The Board has recommended a final dividend of ₹45 per share, which, combined with the interim dividend, brings the total FY26 payout to ₹205 per share. Growth was primarily driven by brand building, supply chain efficiencies, and new product launches in the VMS category.
முக்கிய அம்சங்கள்
Q4 FY26 revenue increased 20% YoY to ₹365 crores with PAT rising 55% to ₹95 crores.Full-year FY26 PAT reached ₹327 crores, up 30% compared to the previous 12-month period.Total dividend for the fiscal year stands at ₹205 per share, including a final dividend of ₹45.New product launches include Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream.Company successfully transitioned its financial year cycle, maintaining strong double-digit growth across metrics.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant margin expansion and the high dividend yield, which underscores the company's strong cash flow. The stock remains a robust pick for those seeking exposure to the defensive healthcare and supplements sector with high shareholder returns.
PGHL Sets August 21, 2026, as Record Date for Dividend and 59th AGM
Procter & Gamble Health Limited (PGHL) has officially announced the record date for its upcoming dividend and 59th Annual General Meeting (AGM). The record date is fixed for August 21, 2026, which will determine the eligibility of shareholders to receive the dividend payment. The 59th AGM is scheduled to be held shortly after on August 27, 2026. The final dividend payout remains subject to the approval of shareholders during the meeting.
முக்கிய அம்சங்கள்
Record date for dividend eligibility and 59th AGM is August 21, 2026The 59th Annual General Meeting is scheduled for August 27, 2026Dividend payment is contingent upon shareholder approval at the AGMOfficial communication sent to both BSE and NSE regarding the timeline
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the company's shares before the record date of August 21, 2026. Monitor the AGM outcomes on August 27 for final approval and payout details.
PGHL Reports FY26 Net Profit of ₹327 Crore; Total Dividend for Year Reaches ₹205 Per Share
Procter & Gamble Health Limited (PGHL) reported a net profit of ₹326.91 crore for the full financial year ended March 31, 2026, on a revenue of ₹1,407.97 crore. The Board has recommended a final dividend of ₹45 per share, bringing the total dividend for the year to a substantial ₹205 per share including previous interim and special payouts. Quarterly performance was robust, with Q4 net profit rising to ₹94.60 crore from ₹77.59 crore in the preceding quarter. Investors should note that year-on-year comparisons are limited as the previous financial year was a shortened nine-month period.
முக்கிய அம்சங்கள்
Full-year FY26 revenue from operations stood at ₹1,40,797 lakhs with a net profit of ₹32,691 lakhs.Recommended a final dividend of ₹45 per share, resulting in a total FY26 dividend of ₹205 per share.Quarterly net profit for the period ended March 31, 2026, grew to ₹9,460 lakhs from ₹7,759 lakhs in the previous quarter.Annual Earnings Per Share (EPS) reached ₹196.94 for the 12-month period ended March 2026.Maintained a strong liquidity position with cash and cash equivalents totaling ₹17,740 lakhs.
👀 கவனிக்க வேண்டியவை
PGHL remains an attractive play for dividend-seeking investors given the high total payout of ₹205 per share. Shareholders should approve the final dividend in the upcoming AGM to realize the remaining ₹45 per share yield.
PGHL to Record INR 32 Crore Profit from Sale of Mumbai Real Estate Assets
Procter & Gamble Health Limited has announced the sale of immovable properties situated in Mumbai. The transaction, executed on April 30, 2026, is expected to generate a profit of approximately INR 32 Crores. This disposal of assets will provide a one-time boost to the company's other income and overall profitability. The move aligns with standard corporate practices of monetizing non-core or underutilized assets to strengthen the balance sheet.
முக்கிய அம்சங்கள்
Sale of immovable properties in Mumbai executed on April 30, 2026Estimated profit of approximately INR 32 Crores from the transactionCompliance with Regulation 30 of SEBI (LODR) Regulations
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive one-time gain that will boost the bottom line; however, focus should remain on core operational growth for long-term assessment.
PGHL Declares ₹160 Interim Dividend Including ₹50 Special Dividend
Procter & Gamble Health Limited has announced a substantial interim dividend of ₹160 per equity share for the financial year 2025-26. This total payout includes a one-time special dividend of ₹50 per share, signaling a significant cash distribution to shareholders. The record date for determining eligibility is set for February 12, 2026. Shareholders must ensure their tax documents and PAN details are updated by February 10, 2026, to avoid higher TDS deductions.
முக்கிய அம்சங்கள்
Declared an interim dividend of ₹160 per equity share with a face value of ₹10 each.The payout includes a one-time special dividend component of ₹50 per share.The record date for determining shareholder eligibility is February 12, 2026.Standard TDS of 10% applies for resident shareholders with PAN; 20% for those without.Submission deadline for tax exemption forms (15G/15H) is February 10, 2026.
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the stock before the record date of February 12, 2026. Existing shareholders should promptly submit tax-related declarations to the RTA by February 10 to optimize their net payout.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
